An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy

Supportive Care in Cancer

Volumn 15, Issue 12, 2007, Pages 1385-1392

  Montoya, Vernon P ^a   Xie, John ^c   Williams, Denise ^c   Woodman, Richard C ^b   Wilhelm, Francois E ^b  

^a North Florida Cancer Center   (United States)

^b Ortho Biotech Products LP   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anemia; Chemotherapy; Epoetin alfa; Erythropoietin; Extended dosing

Indexed keywords

FERROUS SULFATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LABORATORY TEST; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SAMPLE SIZE; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 35349021833     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0263-6     Document Type: Article

References (38)

1. Amgen (2007) Aranesp® (darbepoetin alfa) prescribing information. Amgen Manufacturing Ltd., Thousand Oaks, CA (March)
2. Birgegard G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S (2005) Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68:3-11 (suppl)
3. Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P (2006) Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 11:409-417
4. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
5. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-2221
6. Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597-2605
7. Cheung WK, Danneman B, Wacholtz M, Lau H, Miller D (2004) Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in anemic cancer patients receiving cycling chemotherapy. Blood 104:111b [abstract]
8. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412-3425
9. Amgen (2007) Epogen® (epoetin alfa) prescribing information. Amgen Manufacturing Ltd., Thousand Oaks, CA (March)
10. Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E (2004) Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 30:563-575
11. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
12. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15:1218-1234
13. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G (2006) Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24:2290-2297
14. Glaspy JA (2005) Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. Support Cancer Ther 3:16-20
15. Gregory SA, Xie J, Woodman RC (2005) Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: final results. Blood 106:21b [abstract]
16. Groopman JE, Itri LM (2000) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634 (published erratum appears in J Natl Cancer Inst. 2000;92:497)
17. Henry DH (2004) The evolving role of epoetin alfa in cancer therapy. Oncologist 9:97-107
18. Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC (2006) Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 22:1403-1413
19. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
20. Mughal TI (2004) Current and future use of hematopoietic growth factors in cancer medicine. Hematol Oncol 22:121-134
21. Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L (2004) Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9:90-96
22. Ortho Biotech Products, L.P. (2007) Procrit® (epoetin alfa) prescribing information. Ortho Biotech Products, Raritan, NJ (March)
23. Ortho Biotech Products, L.P. (2007) Procrit® (epoetin alfa) website. Ortho Biotech Dear Healthcare Professional Letter, Available at: http://www.procrit.com. Accessed: March 12
24. Pujade-Lauraine E, Gascon P (2004) The burden of anaemia in patients with cancer. Oncology 67:1-4 (suppl)
25. Reddy PK, Williams D, Wilhelm FE (2006) An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks. Support Cancer Ther 4:56-62
26. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107
27. Rodgers GM III, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Kraut EH, Lin W-C, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P (2006) Cancer- and treatment-related anemia. In: National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology™. v.2.2006. Available at: http://www.nccn.org. Accessed: August 23, 2006
28. Rostad ME (1991) Current strategies for managing myelosuppression in patients with cancer. Oncol Nurs Forum 18:7-15 (suppl)
29. Shasha D, George MJ, Harrison LB (2003) Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98:1072-1079
30. Spivak JL (2005) The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 5:543-555
31. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland Jr KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL (2006) Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 24:1079-1089
32. Tchekmedyian NS (2002) Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Willist Park N Y) 16:17-24
33. Thatcher N (1998) Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 25:23-26 (suppl)
34. Waltzman R, Croot S, Justice GR, Fesen MR, Charu V, Williams D (2005) Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10:642-650
35. Waltzman RJ, Williams D, Braly P (2005) A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 U in anemic patients with cancer receiving chemotherapy. Support Cancer Ther 3:47-53
36. Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16:87-96
37. Weiss MJ (2003) New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 8:18-29 (suppl)
38. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617